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Background: There are many methodological challenges in the conduct and analysis of cluster randomised controlled
trials, but one that has received little attention is that of post-randomisation changes to cluster composition. To illustrate
this, we focus on the issue of cluster merging, considering the impact on the design, analysis and interpretation of trial
outcomes.
Methods: We explored the effects of merging clusters on study power using standard methods of power calculation. We
assessed the potential impacts on study findings of both homogeneous cluster merges (involving clusters randomised to
the same arm of a trial) and heterogeneous merges (involving clusters randomised to different arms of a trial) by
simulation. To determine the impact on bias and precision of treatment effect estimates, we applied standard methods of
analysis to different populations under analysis.
Results: Cluster merging produced a systematic reduction in study power. This effect depended on the number of
merges and was most pronounced when variability in cluster size was at its greatest. Simulations demonstrate that the
impact on analysis was minimal when cluster merges were homogeneous, with impact on study power being balanced
by a change in observed intracluster correlation coefficient (ICC). We found a decrease in study power when cluster
merges were heterogeneous, and the estimate of treatment effect was attenuated.
Conclusions: Examples of cluster merges found in previously published reports of cluster randomised trials were typically
homogeneous rather than heterogeneous. Simulations demonstrated that trial findings in such cases would be unbiased.
However, simulations also showed that any heterogeneous cluster merges would introduce bias that would be hard to
quantify, as well as having negative impacts on the precision of estimates obtained. Further methodological development
is warranted to better determine how to analyse such trials appropriately. Interim recommendations include avoidance of
cluster merges where possible, discontinuation of clusters following heterogeneous merges, allowance for potential loss
of clusters and additional variability in cluster size in the original sample size calculation, and use of appropriate ICC
estimates that reflect cluster size.
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Cluster randomised controlled trials (RCTs), in which
groups of individuals rather than the individuals themselves
are randomised, are conducted for a variety of reasons. The
cluster design is often used when an intervention can be
administered only to a group, such as a service-wide change
or a public health campaign; when there is a risk that an
intervention will affect participants in the nonintervention
arm; or for reasons of cost or convenience. Such RCTs have
a number of methodological challenges in their design,
conduct and analysis, discussions of which can be found in
a number of texts [1,2]. One issue that has received little
attention is the consequence of changes to the composition
of clusters after randomisation, including the merging or
fragmentation of clusters. Cluster RCTs are relatively
common in general practice settings, where general prac-
titioners (GPs) or general practices, rather than individual
patients, are the chosen unit of randomisation. Unfortu-
nately, organisational changes are not uncommon in
primary care, with some practices merging and others
splitting. The number and size of GP practices in the
United Kingdom have changed over time, with a reduction
by 28% in the number of single-handed GP practices
between 2004 and 2009 and a 19% increase in the total
number of GPs. There was a 9% decrease in the number of
GP practices between 1997 and 2007 [3], however, and
organisational changes to meet the challenges of patient
care have been actively encouraged [4].
In this article, we focus on the implications of merging
clusters for the design and analysis of cluster RCTs. We
chose to focus on this effect in cluster RCTs carried out
within primary care, because the reduction in the num-
ber of GP practices in recent years could result in
greater potential for merges to occur in this setting than
in other areas where cluster RCTs are frequently used,
such as schools, communities, factories and hospitals.
There are few incidences of cluster merging reported in
the literature. Using a MEDLINE search (with search terms
‘Trial’ AND ‘primary care’ AND ‘cluster’), we identified
reports of completed cluster RCTs in primary care
published between 2004 and June 2012, with the start date
chosen because 2004 was the year of publication of the
Consolidated Standards of Reporting Trials (CONSORT)
extension for cluster RCTs [5], which require descriptions
of the flow of participants and clusters. We identified 451
potentially useful references in the search.
After assessing the publication texts, we identified 211
reports of cluster RCTs in primary care. From among these,
we found only one in which the authors explicitly reported
a merge of clusters [6]. Foy et al. conducted two parallel
cluster RCTs and reported that a practice merge brought
together practices that were in the same arm of one RCT
and different arms of another. It is not clear whether or
how cluster merging was dealt with in their analysis.To assess the extent of unreported instances of merging
clusters in their RCTs, we contacted authors of papers
published between 2010 and the present. From among the
67 authors contacted, 27 replied (response rate = 40.3%).
Only one of the respondents had experienced a cluster
merge in two practices originally randomised to the same
trial arm. In the analysis, these two practices were treated
as one [7].
Although the number of reported and/or acknowledged
incidence of cluster merging is low, it is not obvious how
RCTconduct and analysis should be handled when clusters
do merge. We suggest that there are a number of simple
options available: (1) discontinue recruitment to affected
clusters, (2) analyse clusters separately as randomised or
(3) analyse the clusters as a new merged cluster. The extent
to which merging of clusters might create difficulties is
likely to depend on the nature of the cluster merges, the
design of the cluster RCT, the arm of the RCT to which
the clusters were originally randomised and the timing of
the merge. For example, if two primary care practices
merge on a purely administrative level, with access to
health-care professionals and patient care unaffected, it
seems reasonable to continue as if such clusters had not
merged and to analyse them as two separate clusters.
Other cases may not be so clear-cut, particularly if patient
care is reorganised following merging of clusters, result-
ing in the potential for contamination. In such cases,
careful consideration of the design will be needed with
regard to the following issues: how recruitment is con-
ducted (identification and enrolment prior to randomisa-
tion or recruitment of individuals postrandomisation),
cohort or cross-sectional design and the nature of the
intervention (for example, at the level of practice/clinician
or patient). In most circumstances, it is unlikely that
merged clusters will be analysed as one cluster if the
clusters were originally randomised to different arms of a
RCT, but it might be considered acceptable in a cross-
sectional design, in which different patients are included
at each measurement time point. The status of parti-
cipants at the time of the cluster merge (for example, the
number who have already completed treatment, the
number part way through treatment and the number in
follow-up) may also have a bearing on the decision.
In the remainder of this article, we explore statistical
issues related to changing cluster composition. Methods
and results are described for continuous outcome mea-
sures, although similar principles apply to binary out-
come measures.
Methods
Impact on study design
The aim of any RCT is to obtain an unbiased estimate
of the treatment effect with sufficient precision to en-
able inferences to be made. In order to accomplish this
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required.
The most common approach to calculating the sample
size for a cluster RCT involves increasing the number of
participants required for an individually randomised trial
by an inflation factor called the design effect. Details of the
sample size calculation can be found elsewhere [8], but we
describe them briefly for a continuous outcome measure.
In the following formulae, the effect to be detected is
denoted by δ, type I error by α and type II error by β.
Calculations are presented for a two-arm RCT, and it is
assumed that the continuous outcome y follows a normal
distribution, y eN μi; σ2i , in each population i (i = 1, 2). If
samples of size ni are collected from population i (i = 1, 2),
then the total sample size required is n = n1 + n2 = (1 + λ)
n1, where λ is the ratio of clusters allocated to each arm of
the RCT, σ2 is the pooled variance and ξυ denotes the
value that satisfies P(Z > ξυ) = υ for Z ~N(0, 1), and is
given by
n ¼ 1þ λð Þ





Withdrawal rates can also be factored into the calcula-
tion, so that if the proportion of participants expected to
drop out is w, the required sample size becomes
n ¼ 1þ λð Þ
2 ξα=2 þ ξβ
 2
σ2
1−wð Þλδ2 : ð2Þ
For a cluster RCT with equal cluster sizes of m, the
design effect is given by 1 + (m − 1)ρ, where ρ is the
intracluster correlation coefficient (ICC) and is calcu-
lated as ρ ¼ σ2b
σ2bþσ2w
, where σ2b is the between-cluster vari-
ance, σ2w is the within-cluster variance and therefore
the total variance is given by σ2 ¼ σ2b þ σ2w . The ICC
is the proportion of the total variance that is due to
between-cluster variability. The sample size required for a
cluster RCT becomes
n ¼ 1þ λð Þ




1þ m−1ð Þρ½ :
Accounting for within-cluster attrition, w, assuming
that attrition occurs uniformly across clusters, the calcu-
lation becomes
n ¼ 1þ λð Þ
2 ξa=2 þ ξβ
 2
σ2
1−wð Þλδ2 1þ m 1−wð Þ−1ð Þρ½ : ð3Þ
Equivalently, when cluster sizes are fixed, the total
number of clusters required is c, wherec ¼ 1þ λð Þ
2 ξα=2 þ ξβ
 2
σ2
m 1−wð Þλδ2 1þ m 1−wð Þ−1ð Þρ½ ; ð4Þ










where Φ is the cumulative distribution function for the
standard normal distribution.
Letting
γ m; c; λ;w; δ; ρð Þ ¼ m 1−wð Þcλδ
2
1þ λð Þ2σ2 1þ m 1−wð Þ−1ð Þρ½ 
ð6Þ
it can be seen that the study power increases monoton-
ically as γ increases. Thus the impact of each parameter
on study power can be examined. The parameters that
will be changed by merging clusters are m, which for
post–cluster merges will be the average cluster size
(rather than fixed); c, the number of clusters; and λ, the
allocation ratio of clusters.
Upon inspection (equation (5)), a simple monotonic
relationship between c and power is apparent, such that
(1 − β)→ 1 as c→∞ and (1 − β)→Φ(−ξα/2) as c→ 0.
It is known that, at larger values of m, the benefit
gained from further increasing the average cluster size
becomes less as the study power plateaus [9]. This has
important consequences for study power if clusters
merge and the average cluster size increases.
The relationship between study power and the ratio of
clusters allocated to each arm of a RCT is nonmono-
tonic, with optimum power at λ = 1, and decreases in
power occurring as the value of λ deviates further from
1. Holding other parameters constant in equation (6),
γ λð Þ∝ λ
1þλð Þ2 and γ′ λð Þ∝ 1−λ1þλð Þ3 , which is positive for λ ∈
[0, 1), negative for λ ∈ (1, ∞) and equal to 0 when λ = 1,
indicating that γ(λ), and therefore the study power,
reaches a maximum point at λ = 1.
Clearly, if a cluster RCT starts with equal-sized clus-
ters and two or more clusters merge, cluster sizes are no
longer equal. Variability in cluster size has a detrimental
effect on study power, as shown by Kerry and Bland
[10]. If cluster sizes follow an underlying distribution
with mean mc and standard deviation σc, and if treat-
ment groups have equal numbers of clusters (λ = 1),
then, as has been shown by a number of authors
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ation in cluster sizes increases. As clusters merge, cluster
size variability increases and the design effect also in-
creases. This implies that, without an increase in sample
size, study power will decrease following cluster merges.
Consider a scenario in which all clusters are of equal
size m and treatment groups receive equal allocations of
the number of clusters. Let the number of clusters be
c ∈ 2ℕ and n(i) denote the size of cluster i (i = 1, …, c).
The standard deviation of cluster size, σc, is therefore 0.
Suppose that k∈ 0; c2
	 

pairs of clusters merge, leaving
c − k clusters in total with n j1ð Þ ¼⋯ ¼ n jkð Þ ¼ 2m for
j1, …, jk ∈ {1, …, c − k}, and n
(i) =m for i ∈ {1, …, c − k}∖
{j1, … jk}. For notational convenience, let S denote the
set {1, …, c − k}∖{j1, …jk}.












c−2kð Þmþ 2kmð Þ ¼ c
c−k
m ð8Þ
Recall that study power increases monotonically with c,
and, holding all other terms in equation (6) fixed, we ob-




this equation becomes ~γ ¼ ~m 1−wð Þ c−kð Þ1þ ~m 1−wð Þ−1ð Þρ  constant. Note
that the constant terms in the expressions for γ and
~γ are equal, but ~m c−kð Þ ¼ cc−k m c−kð Þ ¼ mc . Therefore,
~γ ¼ m 1−wð Þc1þ ~m 1−wð Þ−1ð Þρ  constant, and ~γ≤γ , with equality hold-
ing only if k = 0. Hence, power will be reduced following
cluster merges if no additional clusters are recruited.
































c−kð Þ c−k−1ð Þ
:
ð9Þ
The variation in cluster size increases as k increases
from 0, reaching its maximum before decreasing as k→ c2
(see Figure 1).
If the number of cluster merges differs between the
treatment groups, then the ratio of the number of clus-
ters λ will also be affected. Let ki denote the number of
merges of cluster pairs in treatment group i and cidenote the number of clusters in treatment group i






Because optimum power is achieved when λ = 1, if the
number of cluster merges is unequal between the treat-
ment groups, the study power will be adversely affected.
These formulae have been used to explore the com-
bined impact of the changes in design parameters
graphically.
Impact on analysis: simulation study
Most of the few reported instances of cluster merges in-
volved clusters within the same treatment arm of a RCT
(which we refer to as homogeneous merging). In the one
instance in which data analysis was reported, the result-
ing data were analysed with the merged cluster treated
as a single cluster. We explored, by simulation, the ap-
propriateness of this pragmatic strategy and considered
approaches to analysis when clusters merge that were
randomised to different treatment groups (that is, het-
erogeneous merging).
Cluster RCT data were simulated using the framework
of a multilevel model with a simulated two-arm RCT,
comprising a control group and an intervention group.
Clusters were set to be of equal size with equal alloca-
tion of clusters to treatment arms. The outcome for each
individual was generated as the sum of three compo-
nents, Y ij ¼ μtrtij þ u0j þ ε0ij , where μtrtij was the mean
outcome for the treatment group to which patient i in
cluster j was allocated, u0j was sampled from N 0; σ2b
 
and represented the cluster-level error for all individuals
in that cluster, and ε0ij was sampled from N 0; σ2w
 
and
was used as the individual-level error. Without loss of
generality, σ2b and σ
2
w were chosen so that their sum was
equal to 1. A value of 0.05 was used for the ICC, a com-
monly used value in designing cluster RCTs in primary
care. The total number of clusters was set at 80, and 20
individuals were allocated to each cluster, giving a 5%
significance level at 80% power and an effect size of 0.2.
True treatment group means were given the values μ0 =
0 and μ1 = 0.2.
For each scenario, 1,000 simulations were generated
and a random intercept model was fitted to the resultant
data sets. For model-fitting, we used restricted max-
imum likelihood to improve estimates of the variance
components [15].
We conducted further simulations, keeping the
planned power static at 80% but increasing the cluster
size with a corresponding reduction in the number of
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Total number of merges
 c=10  c=20
 c=40  c=80
Figure 1 Relationship between the variability in cluster size and the number of cluster merges. Graph showing the variability when the
number of clusters before the merges take place is c = 10, 20, 40 and 80 for fixed cluster size before the merges of m = 20.
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individuals per cluster.Homogeneous merges
Homogeneous cluster merges alter cluster size, average
cluster size and, potentially, ICC, all of which have an
impact on study power.Scenario 1 For each homogeneous merge, two clusters
from the same treatment group, which had not already
been involved in a merge, were selected at random to
become a merged cluster. Individual patient outcomes
were left unchanged because it is assumed that treat-
ment is not affected by the merge of clusters. The sce-
nario was simulated for all pairs (k0, k1) ∈ M ×M, where
M = {0, 1, 2, 5, 10, 20} and k0 and k1 are the number of
merges in the control and intervention groups,
respectively.Scenario 2 A further scenario was simulated, to more
closely reflect what might happen in practice. In this
scenario, half of the individuals were assumed to have
completed treatment prior to cluster merge, retaining
the old cluster level error term. The remainder were al-
located to a new merged cluster with a new cluster level
error term applied in generating the outcome.Heterogeneous merges
Two different scenarios were used to simulate heteroge-
neous cluster merges.Scenario 3 The simulated data sets were adjusted in a
similar way as that used for homogeneous merges, with
each merge consisting of one cluster from the control
arm and one from the intervention arm randomly se-
lected to form a merged cluster. With this scenario,
whilst unrealistic in practice and presented here as an
extreme illustration, we assumed that patient outcomes
are unchanged following a merge and represented a
RCT in which all patients completed the intervention
prior to a merge.
Three strategies for analysis were explored: (1) merged
clusters were allocated to the control arm of the study,
(2) merged clusters were allocated to the intervention
arm of the study or (3) merged clusters were eliminated
from the analysis. It was expected that the first two
strategies would lead to bias and that the third, whilst
unbiased, would lead to a loss of power.
Scenario 4 Rather than assume that all patients com-
pleted the intervention prior to the merge, in this sce-
nario, we assumed that only 50% of the patients did so.
The treatment group mean component used to simulate
outcomes for individuals not completing treatment prior
to the merge was adjusted according to treatment group
allocation postmerge. As with scenario 3, analysis was
based on three strategies: (1) merged clusters were allo-
cated to the control group, (2) merged clusters were al-
located to the intervention group or (3) merged clusters
were dropped from the analysis.
Additionally, this scenario was simulated both with
and without those who did not complete treatment prior
to the merge, with individuals analysed according to
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were omitted. This analysis reflected a pragmatic ap-
proach of discontinuing clusters following a merge.
As with homogeneous merges, further simulations
were conducted with increased cluster size and a re-
duced number of clusters, keeping the planned study
power constant at 80%. All simulations and analyses
were conducted using Stata 12 software (StataCorp, Col-
lege Station, TX, USA). Example code for the simula-
tions is given in Additional file 1.
Results
Study design
Equation (6) allowed exploration of the variables that
affect study power when clusters are merged. Figure 2
illustrates this impact when, for example, up to three
merges in treatment group 1 and two merges in treat-
ment group 2 occur. We note that the effect is as ex-
pected on the basis of equation (6). There is a linear
effect on power at each level of merges in each treat-
ment group, and adjustment for potential cluster merges
in study design would be straightforward, although the
choice of assumptions to be made in practice with re-
gard to potential numbers of cluster merges is more
difficult.
Analysis: simulation study
We analysed the complete simulated data sets without
cluster merges. From among the 1,000 simulated data
sets, 826 yielded evidence of a significant treatment dif-
ference at the 5% level, and parameter estimates were all














Merges in trt group 2 = 0
Merges in trt group 2 = 2
Figure 2 Relationship between power and number of cluster merges.
cluster merges in treatment group 2.Homogeneous cluster merges
Scenario 1
Empirical parameter estimates based on equal numbers
of cluster merges are given in Table 1. Estimates of the
treatment effect β1 were unbiased, as expected, with esti-
mates of β0 being consistent with the ‘true’ value of 0.
The variance component estimates have been affected
by the cluster merges, with the between cluster variabil-
ity, σ2b , decreasing as the number of merges increases.
Since the total variation at the individual level is un-
affected, the within cluster variability, σ2w , increased.
Consequently the ICC also decreased. Figure 3 shows
the relationship between the estimate of ICC and the
total number of cluster merges and it appears that the
ICC depends on the average cluster size. Although there
was a small impact on study power, this is rather less
than expected from the results presented earlier, and
was explained by the change to ICC.
Simulations in which unequal numbers of cluster
merges occurred in each of the intervention groups gave
broadly similar results, albeit with a greater loss of
power as the imbalance in cluster allocation to treat-
ments increased. The effect on power is illustrated in
Figure 4.
The same patterns in estimates were observed when
the number and size of clusters was varied, with very
similar results by proportion of clusters merging.Scenario 2
When only 50% of patients are assumed to have com-
pleted prior to a merge a similar pattern was observed.2 3
n trt group 1
Merges in trt group 2 = 1
Graph shows three cluster merges in treatment (trt) group 1 and two
Table 1 Parameter estimates following homogeneous cluster merges: scenario 1a
Number of cluster merges per treatment group
Empirical estimates 0 1 2 5 10 20
Intercept, β0 0.001 (−0.003, 0.005) 0.000 (−0.003, 0.004) −0.001 (−0.005, 0.002) −0.001 (−0.004, 0.002) 0.000 (−0.003, 0.004) −0.003 (−0.006, 0.001)
Treatment effect, β1 0.200 (0.195, 0.205) 0.200 (0.195, 0.205) 0.201 (0.196, 0.206) 0.202 (0.198, 0.207) 0.201 (0.196, 0.206) 0.204 (0.199, 0.209)
σ2b 0.050 (0.048, 0.051) 0.049 (0.048, 0.051) 0.047 (0.046, 0.049) 0.044 (0.043, 0.045) 0.038 (0.037, 0.040) 0.024 (0.023, 0.025)
σ2w 0.950 (0.947, 0.952) 0.952 (0.949, 0.954) 0.954 (0.951, 0.957) 0.955 (0.953, 0.958) 0.962 (0.959, 0.965) 0.975 (0.973, 0.978)
Intracluster correlation
coefficient
0.050 (0.048, 0.051) 0.049 (0.048, 0.051) 0.047 (0.046, 0.049) 0.044 (0.042, 0.045) 0.038 (0.037, 0.039) 0.024 (0.023, 0.025)
Cluster size variance 0 10.1 20.2 49.7 90.4 0
Empirical power 81.8% 80.0% 82.0% 81.7% 80.9% 83.9%
aPatient outcomes are assumed to be unaffected by cluster merge. Total of 80 clusters with 20 patients in each prior to cluster merges. Data are mean (95% confidence interval). σ2b is the between-cluster variance and





































0 10 20 30 40
Total merges
Figure 3 Mean intracluster correlation coefficient estimate by total number of homogeneous cluster merges. Graphed data derived from
simulations, including all pairs of (k0,k1) ∈ M ×M of numbers of merges in each treatment group, with the overlay created using the Lowess
(locally weighted scatterplot smoothing) procedure. ICC, Intracluster correlation coefficient.
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Scenario 3
When each pair of merges consisted of one cluster from
the control arm and one from the intervention arm,
assuming patient outcomes are unaffected by the merge,
the simulations demonstrated attenuation of the treat-
ment effect if all merged clusters were assigned to one
of the treatment groups, with the treatment effect esti-
mate decreasing as the number of merges increased














Figure 4 Observed study power by number of homogeneous cluster
merges in each treatment group, with the overlay created using the Lowewas biased when merged clusters were allocated to the
control group. If the resulting merged clusters were
dropped from the analysis, the treatment effect esti-
mate was unbiased, as expected, but with a loss of
precision.
As with the homogeneous merges, the ICC de-
creased as the total number of merges increased, but
in this scenario the decrease was not sufficient to
prevent the severe loss of power caused by the
merges.20 30 40
 merges
merges. Data including all pairs of (k0,k1) ∈ M ×M of numbers of
ss procedure.
Table 2 Parameter estimates following heterogeneous cluster merges: scenario 3a
Number of cluster merges per treatment group
Empirical estimates 0 1 2 5 10 20
Assigned to control
Intercept, β0 0.001 (−0.003, 0.004) 0.004 (0.000, 0.007) 0.006 (0.002, 0.009) 0.015 (0.012, 0.019) 0.032 (0.029, 0.035) 0.057 (0.054, 0.060)
Treatment effect, β1 0.199 (0.195, 0.204) 0.197 (0.192, 0.202) 0.194 (0.189, 0.198) 0.186 (0.181, 0.190) 0.170 (0.165, 0.175) 0.001 (−0.003, 0.004)
σ2b 0.051 (0.049, 0.052) 0.050 (0.049, 0.051) 0.049 (0.047, 0.0498) 0.048 (0.046, 0.049) 0.046 (0.045, 0.047) 0.039 (0.038, 0.040)
σ2w 0.951 (0.948, 0.954) 0.951 (0.949, 0.954) 0.953 (0.951, 0.956) 0.953 (0.951, 0.956) 0.958 (0.955, 0.961) 0.969 (0.966, 0.971)
Intracluster correlation coefficient 0.050 (0.048, 0.051) 0.050 (0.049, 0.051) 0.049 (0.047, 0.0494) 0.048 (0.046, 0.049) 0.046 (0.044, 0.047) 0.039 (0.037, 0.040)
Empirical power 82.5% 79.0% 78.8% 74.3% 64.3% 46.9%
Assigned to intervention
Intercept, β0 0.002 (−0.002, 0.005) −0.002 (−0.006, 0.001) 0.000 (−0.004, 0.003) 0.001 (−0.003, 0.005) 0.000 (−0.004, 0.004) −0.003 (−0.008, 0.001)
Treatment effect, β1 0.201 (0.197, 0.206) 0.198 (0.194, 0.203) 0.192 (0.187, 0.196) 0.185 (0.180, 0.190) 0.166 (0.161, 0.171) 0.146 (0.141, 0.152)
σ2b 0.050 (0.048, 0.051) 0.050 (0.048, 0.051) 0.049 (0.047, 0.0499) 0.047 (0.046, 0.049) 0.045 (0.043, 0.046) 0.039 (0.038, 0.040)
σ2w 0.948 (0.946, 0.950) 0.950 (0.947, 0.952) 0.950 (0.948, 0.953) 0.956 (0.953, 0.958) 0.958 (0.956, 0.961) 0.968 (0.965, 0.970)
Intracluster correlation coefficient 0.049 (0.048, 0.051) 0.050 (0.048, 0.051) 0.049 (0.047, 0.0498) 0.047 (0.046, 0.048) 0.045 (0.043, 0.046) 0.039 (0.037, 0.040)
Empirical power 82.7% 80.7% 79.5% 72.9% 64.2% 45.1%
Dropped from analysis
Intercept, β0 0.001 (−0.003,0.004) −0.002 (−0.006, 0.001) −0.001 (−0.004, 0.003) −0.004 (−0.007, −0.001) −0.001 (−0.005, 0.003) 0.000 (−0.004, 0.005)
Treatment effect, β1 0.202 (0.197, 0.207) 0.201 (0.196, 0.206) 0.199 (0.194, 0.204) 0.202 (0.197, 0.207) 0.202 (0.196, 0.207) 0.198 (0.192, 0.205)
σ2b 0.051 (0.049, 0.052) 0.050 (0.048, 0.051) 0.050 (0.048, 0.051) 0.049 (0.048, 0.051) 0.049 (0.047, 0.051) 0.050 (0.048, 0.051)
σ2w 0.949 (0.947, 0.952) 0.951 (0.948, 0.953) 0.952 (0.950, 0.955) 0.950 (0.947, 0.953) 0.953 (0.950, 0.956) 0.950 (0.946, 0.953)
Intracluster correlation coefficient 0.051 (0.049, 0.052) 0.050 (0.048, 0.051) 0.050 (0.048, 0.051) 0.049 (0.048, 0.051) 0.049 (0.047, 0.0499) 0.049 (0.048, 0.051)
Empirical power 81.7% 81.0% 78.3% 77.6% 70.2% 53.1%
aPatient outcomes are assumed to be unaffected by cluster merge, indicating that all treatments were finished prior to merge. Total of 80 clusters with 20 patients in each cluster prior to cluster merges. Data are
mean (95% confidence interval). σ2b is the between-cluster variance and σ
2
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Under the assumption of 50% of patients completing
treatment prior to merges of one cluster from the con-
trol arm with one cluster from the intervention arm, the
impact of the heterogeneous merges on the treatment
effect estimates again was attenuation of the treatment
effect, but less extreme than under scenario 3 (Table 3).
Variance components were affected as before, and the
impact on study power, whilst substantial, was not as se-
vere as it was under scenario 3.
If the analysis is restricted to those completing treat-
ment prior to the cluster merge (labelled “Completers
only” in Table 3), then the treatment effect estimates
remained unbiased as expected, but the estimates are
less precise because of the effective reduction in sample
size. The ICC is unaffected by the number of merges,
and study power is slightly affected. As with homoge-
neous merges, the same patterns in estimates were ob-
served when the number and size of clusters were
varied, with very similar results by proportion of clusters
merging.
Discussion
We have demonstrated, through established approaches
to power calculation, that cluster merges have an ad-
verse impact on study power, assuming that the ICC is
unaffected by the change in average cluster size and vari-
ability in cluster size. Given the way in which study
power may be impacted if clusters merge, we suggest
that allowance in this case may need to be made through
recruitment of additional clusters rather than just by in-
creasing the size of the clusters, which is the more com-
mon approach when allowing for loss to follow-up,
although a combination of the two may need to be con-
sidered. This issue is closely related to that of variability
in cluster size and loss to follow-up of clusters, in effect
being a combination of the two. Consequently, the basis
of allowance for cluster merges in the design could be
through using established, previously published methods
such as the one proposed by Taljaard et al. [16]. How-
ever, given the cost of additional clusters, we suggest
that the decision whether to allow for cluster merging
will depend on the perceived likelihood of merges in any
particular study and will be based on knowledge of the
chosen participating sites.
The simulations suggest that homogeneous cluster
merges do not affect the treatment effect estimate. In
our present analysis, we assumed that the cluster size
represents the whole cluster for each cluster, not just a
subset of a larger cluster being analysed. Consequently,
the anticipated loss in study power was offset by the
change in the ICC, such that the impact was much
smaller than expected. The linear relationship obtained
between the estimate of ICC and the total number ofcluster merges indicates that the ICC depends on the
average cluster size. This is in keeping with the relation-
ship between ICC and natural cluster size that has been
shown previously [17,18], with smaller ICC as the aver-
age cluster size increases. This change in ICC would not
occur if the size of the cluster represented the number
from a larger cluster being analysed, because ICC is re-
lated to the natural cluster size rather than the number
sampled, and, in such circumstances, we would expect
to see a loss in study power following any merges.
The simulations therefore indicate that the pragmatic
approach to analysis, treating the new merged cluster as
one cluster, if any homogeneous cluster merges occur is
reasonable, without causing bias or loss of precision in
treatment effect estimate.
The attenuation of the treatment effect estimate fol-
lowing heterogeneous cluster merges is unsurprising,
given the change in cluster composition, although we
note that the impact is minimal when there are only a
few cluster merges. For example, under scenario 3, the
clusters resulting from the merge consist of an equal
number of individuals from each treatment group, and
we might then expect the outcome in these clusters to
be (μ0 + μ1)/2. Following assignment to either treatment
group, the treatment effect will be attenuated, either
through an increase in mean response in the control
group or a decrease in mean response in the interven-
tion group. Consequently, assigning merged clusters to
either treatment group in these circumstances will result
in biased estimates.
Bias following heterogeneous merges can be avoided
by dropping merged clusters from the analysis or by in-
cluding only those individuals who completed treatment
prior to the merge. In practice, this would require that
any merged clusters discontinue the RCT.
In a review of 152 cluster RCTs in primary care,
Eldridge et al. reported an average cluster size of 32 and
an interquartile range of 9 to 82 [19]. In our present
study, we assessed three fixed cluster sizes—20, 40 and
100—that reflect the cluster sizes in RCTs carried out in
primary care. We note that the findings in each scenario
were dependent not on cluster size, only on the propor-
tion of clusters merging. We would not expect the im-
pact to be any different with larger cluster sizes.
We have assumed a fixed cluster size, that is, that the
number of individuals recruited per cluster is the same
across clusters. In some RCTs, this may be unrealistic,
such as in situations where an entire GP practice is in-
cluded. A review of cluster RCTs in primary care showed
that approximately two-thirds have clusters of unequal
size [19]. Methods have already been proposed for inflat-
ing sample size to take into account such variability, the
simplest of which rely on knowledge of the range of
cluster sizes to be included [12]; however, many assume
Table 3 Parameter estimates following heterogeneous cluster merges: scenario 4a
Number of cluster merges per treatment group
Empirical estimates 0 1 2 5 10 20
Assigned to control
Intercept, β0 0.001 (−0.003, 0.004) 0.003 (0.000, 0.007) 0.003 (0.000, 0.007) 0.007 (0.004, 0.011) 0.017 (0.013, 0.020) 0.035 (0.032, 0.0380)
Treatment effect, β1 0.201 (0.196, 0.205) 0.196 (0.191, 0.199) 0.196 (0.191, 0.201) 0.191 (0.186, 0.196) 0.184 (0.179, 0.189) 0.166 (0.159, 0.172)
σ2b 0.050 (0.048, 0.051) 0.049 (0.048, 0.051) 0.049 (0.047, 0.0496) 0.046 (0.045, 0.047) 0.043 (0.042, 0.044) 0.034 (0.033, 0.036)
σ2w 0.950 (0.948, 0.952) 0.951 (0.950, 0.953) 0.952 (0.950, 0.954) 0.957 (0.954, 0.959) 0.962 (0.959, 0.964) 0.971 (0.969, 0.974)
Intracluster correlation coefficient 0.050 (0.048, 0.051) 0.049 (0.048, 0.0499) 0.049 (0.047, 0.0494) 0.046 (0.044, 0.047) 0.042 (0.041, 0.044) 0.034 (0.033, 0.035)
Empirical power 81.2% 78.1% 78.3% 76.8% 72.1% 48.2%
Assigned to intervention
Intercept, β0 0.003 (<0.001, 0.007) 0.001 (−0.003, 0.004) 0.002 (−0.002, 0.006) −0.002 (−0.006, 0.001) 0.001 (−0.004, 0.005) −0.004 (−0.010, 0.002)
Treatment effect, β1 0.198 (0.193, 0.202) 0.195 (0.191, 0.1997) 0.194 (0.189, 0.199) 0.192 (0.187, 0.197) 0.179 (0.174, 0.184) 0.168 (0.162, 0.175)
σ2b 0.049 (0.048, 0.051) 0.050 (0.048, 0.051) 0.048 (0.047, 0.0493) 0.047 (0.046, 0.049) 0.044 (0.042, 0.045) 0.034 (0.033, 0.035)
σ2w 0.949 (0.947, 0.951) 0.951 (0.949, 0.953) 0.953 (0.951, 0.955) 0.956 (0.954, 0.958) 0.963 (0.961, 0.965) 0.973 (0.971, 0.976)
Intracluster correlation coefficient 0.049 (0.048, 0.050) 0.049 (0.048, 0.051) 0.048 (0.047, 0.049) 0.047 (0.046, 0.048) 0.043 (0.042, 0.044) 0.033 (0.032, 0.035)
Empirical power 81.0% 79.7% 77.3% 75.8% 67.2% 50.7%
Completers only
Intercept, β0 −0.000 (−0.004, 0.003) 0.004 (0.000, 0.007) 0.001 (−0.003, 0.005) −0.000 (−0.004, 0.003) 0.001 (−0.002, 0.005) −0.000 (−0.004, 0.003)
Treatment effect, β1 0.200 (0.195, 0.205) 0.195 (0.190, 0.1991) 0.198 (0.193, 0.203) 0.199 (0.194, 0.204) 0.198 (0.193, 0.203) 0.200 (0.194, 0.205)
σ2b 0.050 (0.049, 0.051) 0.050 (0.048, 0.051) 0.050 (0.049, 0.051) 0.051 (0.049, 0.052) 0.050 (0.049, 0.051) 0.050 (0.048, 0.051)
σ2w 0.950 (0.948, 0.952) 0.952 (0.950, 0.954) 0.949 (0.947, 0.952) 0.950 (0.947, 0.952) 0.951 (0.948, 0.953) 0.948 (0.946, 0.951)
Intracluster correlation coefficient 0.050 (0.049, 0.051) 0.050 (0.048, 0.051) 0.050 (0.049, 0.051) 0.050 (0.049, 0.052) 0.050 (0.048, 0.051) 0.050 (0.048, 0.051)
Empirical power 82.3% 79.2% 79.6% 79.5% 77.1% 73.3%
aIn scenario 4, 50% of patient outcomes are assumed to be unaffected by cluster merge, which is akin to 50% completing treatment prior to merge, with the remainder allocated treatment group mean based on
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when calculating sample size [20]. On the basis of the
work presented herein, it might be expected that the im-
pact of clusters merging may be less when the variability
in cluster size has already been considered, but further
work is needed to understand the consequences in this
situation.
Although we have used primary care as the motivating
example throughout this article, given the reduction over
time in the number of GP practices within the United
Kingdom [3], the results presented herein can be applied
to other areas if there is a risk of cluster merges.
We have not yet considered other ways in which the
cluster composition may change, such as merges with
clusters not originally participating in the RCT, which is
not likely to lead to biased estimates, but power is likely
to be affected as the cluster size increases or if more
than two clusters are merged. In addition, clusters may
fragment, resulting in more clusters of smaller average
size. Again, treatment estimates will be unbiased if ori-
ginal treatment allocation applies, but power will be af-
fected. However, consideration would need to be given
to whether these ‘new’ clusters should remain in the
same treatment arm of the RCT, because it might be
more appropriate to randomise if cluster members are
to participate. Cluster membership may also fluctuate
during the course of the study without merging or frag-
mentation of clusters, particularly in primary care, where
patients leave and join a practice, an issue discussed by
Diehr et al. [21] in relation to survey design.
The CONSORT extension for cluster RCTs requires
the flow of clusters, as well as the flow of patients, to be
described. Our review of the literature indicates that,
even when authors have revealed changes to clusters,
they did not do so in a manner that allowed full under-
standing. Clearly, authors need to follow reporting
guidelines more closely, and journal editors should em-
phasise the need to do so. Investigators also need to
consider whether changes need to be made to protocols,
either to preempt any possible changes to cluster com-
position, defining up front how they should be dealt with
or in response to such changes.
Conclusions
Adjusting the design effect in power calculations for
variability in cluster size and changes in average cluster
size, we note that merging of clusters in cluster RCTs is
expected to result in a loss of power. However, the simu-
lations conducted examining homogeneous cluster
merges resulted in a much smaller loss of power, to the
extent of being largely unimportant, because the ob-
served ICC decreased. This suggests that the relation-
ship of ICC with cluster size should not be ignored at
the planning stage.A pragmatic approach in which the merged clusters
are analysed as one new cluster, following homogeneous
cluster merges, results in acceptable treatment effect es-
timates, so such merges should not cause concern. How-
ever, heterogeneous merges are problematic, leading to
biased treatment effect estimates unless merged clusters
are discontinued. If such clusters are discontinued, the
estimate is unbiased, but with a loss of precision. Allow-
ance for loss to follow-up at the cluster level as well as
at the individual level might be advisable at the planning
stage of a cluster RCT. Further research is warranted to
fully understand the impact of other changes to clusters
postrandomisation and to develop appropriate ap-
proaches to statistical analysis.
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